Literature DB >> 28594298

To stop or not to stop disease modifying therapies in secondary progressive multiple sclerosis, that is the question.

Emanuele D'Amico1, Tjalf Ziemssen2, Salvatore Cottone3.   

Abstract

Entities:  

Keywords:  DMT; Multiple sclerosis; outcome; secondary progressive multiple sclerosis; therapy

Year:  2017        PMID： 28594298     DOI： 10.1080/14737175.2017.1340831

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN： 1473-7175            Impact factor:   4.618


× No keyword cloud information.
  5 in total

Review 1.  The Role of Transcranial Magnetic Stimulation as a Surrogate Marker of Disease Activity in Patients with Multiple Sclerosis: A Literature Review.

Authors:  Muhannad M Alsharidah; Mohammad Uzair; Sarah S Alseneidi; Afnan A Alkharan; Reem Fahd Bunyan; Shahid Bashir
Journal:  Innov Clin Neurosci       Date:  2022 Jan-Mar

2.  Stopping Interferon Beta 1b Does Not Influence the Risk of Disability Accrual in Non-Active SPMS: Results from an Italian Real-World Study.

Authors:  Aurora Zanghì; Emanuele D'Amico; Francesco Patti; Carlo Avolio
Journal:  Int J Environ Res Public Health       Date:  2022-05-17       Impact factor: 4.614

3.  Use and cost of disease-modifying therapies by Sonya Slifka Study participants: has anything really changed since 2000 and 2009?

Authors:  Sarah L Minden; R Philip Kinkel; Helene T Machado; Jonathan S Levin; Meredith B Rosenthal; Lisa I Iezzoni
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-02-20

4.  Two Sides to Every Story: Perspectives from Four Patients and a Healthcare Professional on Multiple Sclerosis Disease Progression.

Authors:  Jeri Burtchell; Kristen Fetty; Katelyn Miller; Kit Minden; Daniel Kantor
Journal:  Neurol Ther       Date:  2019-07-04

5.  Does a modifiable risk factor score predict disability worsening in people with multiple sclerosis?

Authors:  Claudia H Marck; Zoe Aitken; Steve Simpson; Tracey J Weiland; George A Jelinek
Journal:  Mult Scler J Exp Transl Clin       Date:  2019-10-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.